These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31505052)

  • 1. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.
    Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH
    J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
    Gupta A; Cao W; Chellaiah MA
    Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
    Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
    Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.
    Casimiro S; Mohammad KS; Pires R; Tato-Costa J; Alho I; Teixeira R; Carvalho A; Ribeiro S; Lipton A; Guise TA; Costa L
    PLoS One; 2013; 8(5):e63153. PubMed ID: 23696795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
    Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
    Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis.
    Hinz N; Baranowsky A; Horn M; Kriegs M; Sibbertsen F; Smit DJ; Clezardin P; Lange T; Schinke T; Jücker M
    Cells; 2021 Feb; 10(2):. PubMed ID: 33670586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
    Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
    J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
    Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
    Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
    Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
    Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
    Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
    Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
    Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
    Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Runx2 induces bone osteolysis by transcriptional suppression of TSSC1.
    Wang DC; Wang HF; Yuan ZN
    Biochem Biophys Res Commun; 2013 Sep; 438(4):635-9. PubMed ID: 23933319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
    Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
    BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of osteoclastic activity in prostate cancer skeletal metastases.
    Keller ET
    Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.
    Pratap J; Wixted JJ; Gaur T; Zaidi SK; Dobson J; Gokul KD; Hussain S; van Wijnen AJ; Stein JL; Stein GS; Lian JB
    Cancer Res; 2008 Oct; 68(19):7795-802. PubMed ID: 18829534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.